The.amaged retinal blood vessels and other retinal changes are visible to an eye doctor when an examination of the retina funds exam is performed. Vision lost to diabetic retinopathy is sometimes irreversible. The floating spots are haemorrhages that require prompt treatment. The same scene as viewed by a person normal vision Top and with enter advanced diabetic retinopathy. no dataOphthalmology. 4th ed. Sickle cell anaemia also affects the blood vessels in the eyes. http://experteyedoc.macsverige.org/2016/12/05/uncovering-elementary-solutions-in-glaucoma/Whereas this can, of course, occur due to various medical conditions, such as a stroke or Alzheimer’s disease, it can also occur from a… read more » Tremor need not be Parkinson’s disease: There is the tendency to believe that any tremor symptom, or shakiness, means Parkinson’s disease . Today, many retinal problems are treated with lasers. Most often, diabetic retinopathy has no symptoms until the damage to your eyes is severe. The retina can swell and vision will be affected. Studies such as the Diabetes Control and Complications Trial acct have shown that controlling diabetes slows the onset and worsening of diabetic retinopathy. Deteriorating blood vessels can become blocked or deformed. Solar retinopathy due to direct sunlight exposure.
Regeneron’s future depends heavily on Praluent. While sales for the cholesterol drug are picking up momentum, Praluent hasn’t been a rousing success yet. The problem is that payers have been reluctant to open their purse strings. Regeneron and partner Sanofi ( NYSE:SNY ) expect that to change once the results from a major cardiovascular outcomes study are available. Some had hoped that studywould wrap up sooner than planned if an interim analysis found overwhelming positive results. Those hopes weredashed, however, when Regeneron and Sanofi announced on Nov. 17 that the independent data monitoring committee recommended the study continue into next year. Final results probably won’t be available until early 2018. Praluent should eventually be a big winner for Regeneron, though. So should experimental rheumatoid arthritis drug sarilumab. Unfortunately, there’s been bad news for sarilumab also. The U.S.
For the original version including any supplementary images or video, visit http://www.fool.com/investing/2016/11/18/better-buy-regeneron-pharmaceuticals-inc-vs-novart.aspx?source=iedfolrf0000001